Yolk Sac Tumor

Search with Google Search with Bing
Information
Disease name
Yolk Sac Tumor
Disease ID
Description
Disease area statistics
Chromosome band
Gene symbol Chromosome Start Stop The number of variant
ATM 11 108,222,804 108,369,102 4
APC 5 112,737,885 112,846,239 2
C11orf65 11 108,382,755 108,467,529 2
CEBPA 19 33,299,934 33,302,534 2
PMS2 7 5,970,957 6,009,122 2
TP53 17 7,668,421 7,687,490 2
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT02375204 Active, not recruiting Phase 3 Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors August 5, 2015 June 2024
NCT06341998 Completed Phase 2/Phase 3 Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children June 1, 2020 February 1, 2024
NCT04715191 Not yet recruiting Phase 1 Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors July 3, 2024 July 3, 2041
NCT06198296 Not yet recruiting Phase 1 Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells January 1, 2026 February 1, 2043
NCT05103631 Recruiting Phase 1 Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors June 17, 2021 December 2039
NCT04377932 Recruiting Phase 1 Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors December 8, 2021 February 1, 2040
NCT05564026 Recruiting Molecular Epidemiology of Pediatric Germ Cell Tumors April 12, 2023 June 30, 2027